AFSP expert touts promise of ketamine‐buprenorphine approach
Mental Health Weekly May 25, 2026 DOI: 10.1002/mhw.34881 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | News report Peer reviewed |
|---|---|
| Intervention | Ketamine |
| Topics | Esketamine Ketamine |
| Key points | Reports that ketamine followed by ultra-low-dose buprenorphine may sustain reductions in suicidal ideation, and that suicide prevention experts say the approach may help address a long-standing gap in treatment during high-risk periods following a crisis. |
Abstract
New findings published this month in The American Journal of Psychiatry (AJP) on the use of ketamine followed by ultra‐low‐dose buprenorphine to sustain reductions in suicidal ideation are drawing attention from suicide prevention experts, who say the approach may help address a long‐standing gap in treatment during high‐risk periods following a crisis (see related story, p. 3).